The biotech company is considering a merger, acquisition, or other transaction. It previously discontinued its lead drug candidates and cut most of its workforce, with restructuring costs estimated at $15 million to $19 million. The CFO will step down once a deal is reached.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
